Protagonist Therapeutics, Inc. (PTGX) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Company performance

Current Price

as of Jan 17, 2025

$36.82

P/E Ratio

13.81

Market Cap

$2.19B

Description

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Metrics

Overview

HQNewark, CA
SectorHealth Technology
IndustryBiotechnology
TickerPTGX
Price$36.82+0.77%

Trading Information

Market cap$2.19B
Float94.11%
Average Daily Volume (1m)656,937
Average Daily Volume (3m)670,779
EPS$2.82

Company

Revenue$323.79M
Rev growth (1yr)N/A
Net income-$33.21M
Gross margin86.16%
EBITDA margin-872.86%
EBITDA-$40.81M

EV$2.32B
EV/Revenue7.17
P/E13.81
P/S7.02
P/B4.12

Documents

Earnings Calls

Earnings Report 2020Q4

Earnings Report (2021-03-10)

Factset Street Account

Protagonist Therapeutics reports Q3 EPS ($0.58) vs FactSet ($0.69) [6 est, ($0.76)-(0.67)] ($15.41, 0.00) (2023-11-03T18:16:47Z)

Protagonist Therapeutics initiated overweight at Capital One Securities ($14.08, 0.00) (2023-10-30T10:34:03Z)

Protagonist Therapeutics holder Point72 discloses 5.5% passive stake - 13G ($20.73, 0.00) (2023-12-18T21:20:36Z)

Protagonist Therapeutics announces advancement of JNJ-2113 across multiple indications ($16.24, 0.00) (2023-10-09T11:04:14Z)

Protagonist Therapeutics acheives $50M milestone after third patient dosed in phase 3 study of JNJ-2113 in moderate-to-severe psoriasis ($15.11, 0.00) (2023-11-01T20:43:31Z)

Protagonist announces two new phase 3 ICONIC studies in psoriasis evaluating JNJ-2113 in head-to-head comparisons with deucravacitinib ($17.23, 0.00) (2023-11-27T14:09:07Z)